The impact of MYC point mutations on cancer development and progression is poorly explored, particularly if compared with other MYC genetic alterations, such as translocations and amplifications. MYC point mutations were first observed more than 40 years ago in lymphoid malignancies, and some of these were functionally characterized. In the following decades, only a few studies on MYC point mutations were reported until recently when analyses of the myriad cancer-related high-throughput sequencing studies brought new life to this research topic and expanded the range of malignancies involved. However, to date, all this information can be retrieved only by consulting the specific literature or navigating publicly available databases, and a proper collection and systematic description of these genetic changes are urgently needed. In this review, we run through the steps of the MYC point mutations line of research with a comprehensive illustration of the recurrent variants occurring in the MYC coding, noncoding, and regulatory regions in cancer. With this work, we also aim to highlight the current gaps in knowledge to stimulate research in this field, which could ultimately result in the realization of its translational potential.
Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5–15% of DLBCL cases harbor MYC gene translocations, often involving immunoglobulin genes as a translocation partner, and concomitant point mutations, correlating with a poor response to standard therapies. However, given the difficulty in detecting these abnormalities requiring specialized techniques and high-quality specimens, the use of metabolomics (i.e., the study of small metabolites in body fluids and tissues) can offer a useful alternative for the identification of high-risk DLBCL patients. Amino acids (AAs) are metabolites essential in the process of tumorigenesis and can increase immune escape and drug resistance. Therefore, we review the use of metabolomics to improve the diagnosis and prognosis in DLBCL patients in relation to the MYC role in the regulation of amino acid metabolism, as these metabolites may be used as potential biomarkers in a clinical environment.
This study evaluates the effects of hypergravity (HG) on a neurodegenerative model in vitro, looking at how HG influences Tau protein aggregation in Mouse Hippocampal Neuronal Cells (HT22) induced by neurofibrillary tangle seeds. Overall, 50× g significantly, synergistically, reduced the Tau aggregate Area when combined with ERK-inhibitor PD-0325901, correlating with decreased phosphorylation at critical residues pS262 and pS396. These findings suggest HG treatments may help mitigate cytoskeletal damage linked to Tau aggregation.